Delisting of Securities of ALSERES Pharmaceuticals, Inc. (ALSE) From The NASDAQ Stock Market
7/17/2009 8:51:38 AM
More...
|
ALSERES Pharmaceuticals, Inc. (ALSE) Shares Begin Trading on the Pink Sheets OTC Market
5/8/2009 11:29:21 AM
More...
|
ALSERES Pharmaceuticals, Inc. (ALSE) and BioAxone Therapeutic Inc. Amend License Agreement for Cethrin(R) and Rho Inhibitor Technology
4/30/2009 10:46:19 AM
More...
|
ALSERES Pharmaceuticals, Inc. (ALSE) Receives Notice of De-Listing of Its Securities for Failure to Regain Compliance with Continued Listing Requirements
4/14/2009 12:26:12 PM
More...
|
ALSERES Pharmaceuticals, Inc. (ALSE) Receives Special Protocol Assessment Agreement from FDA for Phase III Trial of Altropane
4/7/2009 8:19:52 AM
More...
|
ALSERES Pharmaceuticals, Inc. (ALSE) Complies with NASDAQ Rule Regarding Recently Filed 10-K
3/31/2009 11:33:13 PM
More...
|
ALSERES Pharmaceuticals, Inc. (ALSE) Reports 2008 Results
3/26/2009 11:24:09 AM
More...
|
ALSERES Pharmaceuticals, Inc. (ALSE) Announces $200,000 Financing
2/27/2009 9:41:47 AM
More...
|
ALSERES Pharmaceuticals, Inc. (ALSE) Completes Enrollment in First Stage of the Altropane(R) POET-2 Phase III Program
2/3/2009 1:20:06 PM
More...
|
ALSERES Pharmaceuticals, Inc. (ALSE) Announces $1 Million Financing
1/13/2009 8:55:55 AM
More...
|
|